paper summary2
TRANSCRIPT
-
8/14/2019 Paper Summary2
1/27
Paper Summary
Monotone Smoothing with Application to
Dose-Response Curves and
the Assessment of Synergism
Colleen Kelly and John Rice, Biometrics,
Vol. 46, No. 4, (Dec., 1990), pp. 1071-1085
-
8/14/2019 Paper Summary2
2/27
Outline
Introduction
Monotone Smoothing
Assessing SynergismBootstrap Method
Procedure
ApplicationResult
-
8/14/2019 Paper Summary2
3/27
Monotone Smoothing
0 1 1
1
To monotone smoothing is based on spline
function. Given a partition
... of an interval [ , ]
a spline function is a polynomial on each
interval [ , ).
We shall refer to the as "kno
p
j j
i
a b a b
ts".
-
8/14/2019 Paper Summary2
4/27
Monotone Smoothing
Given data points ( , ) ( 1,..., ), a smoothing
spline is the function that minimizes
i i x y i n
1
2 2
1
( ) ( ( )) [ ( )]n
n x
i ix
i
Q Y x x dx
The minimizing is a cubic spline with
a knot at every data point.
-
8/14/2019 Paper Summary2
5/27
Monotone Smoothing
as 0, tends to an interpolant of the data.
The smaller is, the quicker the running time,
especially when 0.
p
as , tends to the LS line fit to the data.
-
8/14/2019 Paper Summary2
6/27
-
8/14/2019 Paper Summary2
7/27
-
8/14/2019 Paper Summary2
8/27
Monotone Smoothing
Knot placement should depend on the density
of data points or on local behavior of curve.
Thus we control smoothing only with .
1. Chosen the amount of smoothing to apply .
2. Leave-one-out cross-validation.
3. Doing a preliminary QR decomposition.
-
8/14/2019 Paper Summary2
9/27
Assessing Synergism
Synergistic if its effect is more than
would be expected form what is known
about the effect of the individuak
constituent.
Antagonistic if the effect is less.
Asynergistic if effect is the same.
-
8/14/2019 Paper Summary2
10/27
Assessing Synergism
Definition of synergism:
Let the repsone to dosages and of two
drug be denote by ( , ).
Assume 0 0, and ( ,0) (0, ) are
monotone.
x y
f x y
x y f x f y
-
8/14/2019 Paper Summary2
11/27
Assessing Synergism
For given response value let and be
those dosages such that ( ,0) (0, ) .
if ( , ) , 1.
Synergistic if left side is less than 1.
Antagonistic if it is greater than 1.
z z
z z
z z
z x y
f x f y z
x y f x y z x y
-
8/14/2019 Paper Summary2
12/27
Bootstrap Method
Parametric bootstrap samples
Model could be binomial or poisson.
2
*( )
i
*(b) *( )
, ~(0, ), independent.bootstrap residuals
: 1... : 1...
bootstrap sample for Y is Y .
b
b
Y X
i n b B
X
-
8/14/2019 Paper Summary2
13/27
Procedure
Monotone spline
Parametric bootstrap sample
Check synergism
-
8/14/2019 Paper Summary2
14/27
Application I
Data form Le Pelley and Sullivan
(1936).
Alcoholic solutions of rotenone,
pyrethrins, and a mixture of the two.
The mixture series was 1:5 ratio and
1:15 ratio.
-
8/14/2019 Paper Summary2
15/27
-
8/14/2019 Paper Summary2
16/27
-
8/14/2019 Paper Summary2
17/27
-
8/14/2019 Paper Summary2
18/27
-
8/14/2019 Paper Summary2
19/27
Application I
2
2
Calculations
for the 1:5 ratio, (3) 81.19 was synergism.
for the 1:15 ratio, (3) 11.72 which is
not significant at 0.05.
-
8/14/2019 Paper Summary2
20/27
Application I
Bliss (1939);
Finney, using probit analysis (1952);
Chou and Talalay with median effect
analysis (1983)
All investigators concluded there was
synergism in the 1:5 ratio and slight
synergism in the 1:15 ratio.
-
8/14/2019 Paper Summary2
21/27
Application II
Data form Dr Stephen Howell of the UCSD
Cancer Center.
Ovarian cancer may be treated by VP-16 and
DPM.
There are 6 concentration levels for each
individual dose-reponse curve, with 18
observations.There are 4 combination doses ratio 1:150 of
VP-16/DPM.
-
8/14/2019 Paper Summary2
22/27
-
8/14/2019 Paper Summary2
23/27
-
8/14/2019 Paper Summary2
24/27
-
8/14/2019 Paper Summary2
25/27
Application II
Parametric bootstrap based on Poisson
model for the random variability under
asynergy.
Responses are to increasing
concentrations of a conmbination of both
drugs in a 1:150 ratio.
-
8/14/2019 Paper Summary2
26/27
Reference
Howell, S. B., Sanga, R., Vick, J., and Abramson, I. (1989a).
Comparison of the Synergistic Potentiation of Etoposide,
Doxorubicin, and Vinblastine Cytotoxicity by Dipyridamole.
Cancer Research 49, 4147-4153.
, , lecture5, lecture6, lecture7.
-
8/14/2019 Paper Summary2
27/27
Thank you for your listening.